Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Receivables: 2010-2024

Historic Change in Receivables for Tg Therapeutics (TGTX) over the last 5 years, with Dec 2024 value amounting to $78.1 million.

  • Tg Therapeutics' Change in Receivables rose 5.45% to $33.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.7 million, marking a year-over-year increase of 95.87%. This contributed to the annual value of $78.1 million for FY2024, which is 52.84% up from last year.
  • Tg Therapeutics' Change in Receivables amounted to $78.1 million in FY2024, which was up 52.84% from $51.1 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Change in Receivables ranged from a high of $78.1 million in FY2024 and a low of -$1.4 million during FY2022.
  • Its 3-year average for Change in Receivables is $42.6 million, with a median of $51.1 million in 2023.
  • Its Change in Receivables has fluctuated over the past 5 years, first crashed by 200.00% in 2022, then soared by 3,778.40% in 2023.
  • Yearly analysis of 4 years shows Tg Therapeutics' Change in Receivables stood at $1.4 million in 2021, then slumped by 200.00% to -$1.4 million in 2022, then surged by 3,778.40% to $51.1 million in 2023, then soared by 52.84% to $78.1 million in 2024.